NASDAQ:ANAB - AnaptysBio Stock Price, Forecast & News

AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."

AnaptysBio Inc (NASDAQ:ANAB) released its quarterly earnings results on Friday, November, 8th. The biotechnology company reported ($1.15) earnings per share for the quarter, missing analysts' consensus estimates of ($1.09) by $0.06. During the same quarter last year, the company posted ($0.66) EPS. View AnaptysBio's Earnings History.

AnaptysBio is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for AnaptysBio.

9 equities research analysts have issued 12-month target prices for AnaptysBio's shares. Their forecasts range from $12.00 to $140.00. On average, they expect AnaptysBio's stock price to reach $79.25 in the next twelve months. This suggests a possible upside of 390.4% from the stock's current price. View Analyst Price Targets for AnaptysBio.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last year. There are currently 1 sell rating, 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AnaptysBio.

News coverage about ANAB stock has trended very negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. AnaptysBio earned a news sentiment score of -3.5 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for AnaptysBio.

AnaptysBio saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 4,420,000 shares, an increase of 11.3% from the January 15th total of 3,970,000 shares. Based on an average daily trading volume, of 999,800 shares, the days-to-cover ratio is currently 4.4 days. Approximately 18.1% of the shares of the stock are sold short. View AnaptysBio's Current Options Chain.

Some companies that are related to AnaptysBio include Akcea Therapeutics (AKCA), Arvinas (ARVN), Aimmune Therapeutics (AIMT), TG Therapeutics (TGTX), Alder Biopharmaceuticals (ALDR), Corcept Therapeutics (CORT), Innoviva (INVA), Constellation Pharmaceuticals (CNST), ZEALAND PHARMA/S (ZEAL), Theravance Biopharma (TBPH), IGM Biosciences (IGMS), Nabriva Therapeutics (NBRV), Madrigal Pharmaceuticals (MDGL), BELLUS Health (BLUSF) and Endo International (ENDP).

Based on aggregate information from My MarketBeat watchlists, some companies that other AnaptysBio investors own include Editas Medicine (EDIT), ImmunoGen (IMGN), NVIDIA (NVDA), AbbVie (ABBV), Alibaba Group (BABA), Baidu (BIDU), Baozun (BZUN), Crispr Therapeutics (CRSP), Momo (MOMO) and bluebird bio (BLUE).

(ANAB) raised $60 million in an initial public offering on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

AnaptysBio's stock is owned by many different of retail and institutional investors. Top institutional shareholders include EcoR1 Capital LLC (7.25%), State Street Corp (7.17%), Tang Capital Management LLC (6.80%), Boxer Capital LLC (4.79%), Perceptive Advisors LLC (3.69%) and BVF Inc. IL (3.46%). Company insiders that own AnaptysBio stock include Dominic Piscitelli, Hamza Suria, Marco Londei and Nicholas Lydon. View Institutional Ownership Trends for AnaptysBio.

ANAB stock was sold by a variety of institutional investors in the last quarter, including FMR LLC and SG Americas Securities LLC. Company insiders that have sold AnaptysBio company stock in the last year include Hamza Suria and Marco Londei. View Insider Buying and Selling for AnaptysBio.

ANAB stock was bought by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Tang Capital Management LLC, Boxer Capital LLC, Perceptive Advisors LLC, State Street Corp, BVF Inc. IL, Krensavage Asset Management LLC and Broadfin Capital LLC. View Insider Buying and Selling for AnaptysBio.

Shares of ANAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ANAB stock can currently be purchased for approximately $16.16.

AnaptysBio has a market capitalization of $438.47 million and generates $5 million in revenue each year. The biotechnology company earns $-61,660,000.00 in net income (profit) each year or ($2.50) on an earnings per share basis. AnaptysBio employs 78 workers across the globe.View Additional Information About AnaptysBio.

The official website for AnaptysBio is http://www.anaptysbio.com/.

AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-362-6295 or via email at [email protected]